6 citations,
February 2013 in “Medical Oncology” Certain genetic variants increase the risk of resistance to hormone therapy in prostate cancer patients.
57 citations,
April 2009 in “The Journal of Steroid Biochemistry and Molecular Biology” Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.
38 citations,
December 2009 in “Therapeutic Advances in Medical Oncology” The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.
402 citations,
August 2011 in “Cancer research” Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.
February 2024 in “Cancers” New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
21 citations,
February 2021 in “Frontiers in Endocrinology” Hormones affect prostate health and disease, with certain hormone imbalances linked to prostate cancer and benign prostatic hyperplasia.
9 citations,
September 2009 in “The Prostate” Finasteride doesn't improve survival in LNCaP tumor model during off-cycle of therapy.
119 citations,
July 2016 in “Annals of the New York Academy of Sciences” Vitamin D has potential benefits for cancer prevention, heart health, diabetes, obesity, muscle function, skin health, and immune function, but clinical results are mixed and more research is needed.
46 citations,
April 2016 in “Journal of Investigative Dermatology” New genes found linked to balding, may help develop future treatments.
34 citations,
July 2020 in “Frontiers in immunology” Androgens may influence T cells, contributing to higher autoimmune liver disease risk in women.
7 citations,
January 2013 in “European Urology” 5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
January 2019 in “Przegląd Dermatologiczny” Chemotherapy with docetaxel can cause painful nail and skin side effects that may lead to stopping treatment.
December 2023 in “International Journal of Molecular Sciences” Men with early balding showed higher levels of certain genes linked to hair loss and possibly prostate cancer.
22 citations,
January 2017 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” A new method accurately measures nine specific hormones in human blood.
11 citations,
January 2017 in “Journal of Endocrinology/Journal of endocrinology” Female mice with disrupted 5α-reductase 1 had significant metabolic issues, including stress response problems, insulin resistance, liver fat buildup, and obesity.
23 citations,
May 2019 in “Expert Opinion on Therapeutic Patents” New androgen receptor modulators show promise for treating diseases like prostate cancer and muscle wasting.
2 citations,
February 2020 in “Journal of Investigative Surgery” Flutamide-induced hypospadias in rats slows down early wound healing.
54 citations,
January 2023 in “Signal Transduction and Targeted Therapy” New therapies are being developed that target integrin pathways to treat various diseases.
49 citations,
March 2017 in “PubMed” Enhancers and super-enhancers are key in controlling specific gene activity and can play a role in cancer development.
6 citations,
February 2023 in “Journal of nanobiotechnology” The new anti-acne treatment HA-P5 effectively reduces acne by targeting two key receptors and avoids an enzyme that can hinder treatment.
1 citations,
January 2022 in “European Journal of Pharmacology” Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.
17 citations,
January 2015 in “MedChemComm” New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.
70 citations,
September 2017 in “Expert opinion on therapeutic patents” The review suggests that while many AKR1C3 inhibitors show promise for treating certain cancers, more research is needed to confirm their effectiveness in humans.
4 citations,
January 2013 in “PubMed” Testosterone and finasteride raise insulin and zinc, lower chromium in male rats.
45 citations,
January 2020 in “International Journal of Molecular Sciences” Some natural compounds may help overcome drug resistance in certain cancers, but more research is needed.
45 citations,
May 2012 in “The Journal of Steroid Biochemistry and Molecular Biology” Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.
7 citations,
January 2023 in “Journal of Hematology & Oncology” Using protein degradation to fight cancer drug resistance shows promise but needs more precise targeting and fewer side effects.
58 citations,
January 2003 in “Thrombosis and Haemostasis” Testosterone may slow down wound healing and increase inflammation.
31 citations,
January 2017 in “Advances in Experimental Medicine and Biology” Low testosterone and 5α-reductase inhibitors can harm men's metabolic and sexual health; testosterone therapy may help, but discussing 5α-RIs' side effects is important.
30 citations,
July 2019 in “Endocrinology” Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.